ReviewEuropean journal of cancer (Oxford, England : 1990)2023
DNA methylation markers in the detection of hepatocellular carcinoma.
Review in European journal of cancer (Oxford, England : 1990), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 43 citations in OpenAlex.
- Cell-free DNA methylation markers in the diagnosis of hepatitis B virus-related- hepatocellular carcinoma: a review.Molecular biology reports · 2026Review
- Bioinformatic characterization of SLC25A39 across cancers with validation in hepatocellular carcinoma.Discover oncology · 2026Article
- Prognostic value of PRAME gene promoter methylation and expression in hepatocellular carcinoma.Clinical epigenetics · 2026Article
- Pre-operative risk assessment of hepatocellular carcinoma recurrence in liver transplant recipients by non-invasive detection of pre-existing genetic lesions.Clinical and molecular hepatology · 2026Article
- Curcumin in High Doses Reverses the UV-B-InducedPharmaceuticals (Basel, Switzerland) · 2026Article
- Choline and DNA methylation: impact across metabolic, oncogenic and neurodevelopmental disorders.Clinical epigenetics · 2026Review
- Artificial intelligence driven exposome and multi omics integration for biomarker discovery in liver cancer: a literature review.Frontiers in immunology · 2026Review
- Navigating the Labyrinth of Hepatocellular Carcinoma: Leveraging AI/ML for Precision Oncology.Oncology research · 2026Review
- Epigenetic silencing ofFrontiers in genetics · 2026Article
- Update on Methylation Markers as Risk Predictors of Hepatocellular Carcinoma.Gastroenterology & hepatology · 2026Article
- Predicting bevacizumab efficacy: the emerging role of ACTL6B in colorectal cancer.Journal of gastrointestinal oncology · 2025Article
- Liver, ageing and disease.Nature reviews. Gastroenterology & hepatology · 2025Review
- Intratumoral Microbe Correlated with Expression of DNA Methylation Genes in Hepatocellular Carcinoma.Digestive diseases and sciences · 2025Article
- Integrated Analysis of PSMB8 Expression and Its Potential Roles in Hepatocellular Carcinoma.Digestive diseases and sciences · 2025Article
- Integrating cell-free DNA methylation of SEPT9 and SFRP2 into a machine learning model for early diagnosis of HCC.Biomarkers in medicine · 2025Article
- A comparison of hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: a bioinformatics analysis.Translational cancer research · 2025Article
- Clinical performance evaluation of a plasma dual-target methylation test for the detection of primary liver cancer: a multicenter study.Clinical epigenetics · 2025Observational
- Multidimensional pan-cancer analysis reveals the impact of PPIA on tumor epigenetic modifications and immune regulation.Scientific reports · 2025Article
- How chronic inflammation fuels carcinogenesis as an environmental epimutagen.Discover oncology · 2025Review
- The epigenetic basis of hepatocellular carcinoma - mechanisms and potential directions for biomarkers and therapeutics.British journal of cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and has a poor prognosis. Epigenetic modification has been shown to be deregulated during HCC development by dramatically impacting the differentiation, proliferation, and function of cells. One important epigenetic modification is DNA methylation during which methyl groups are added to cytosines without changing the DNA sequence itself. Studies found that methylated DNA markers can be specific for detection of HCC. On the basis of these findings, the utility of methylated DNA markers as novel biomarkers for early-stage HCC has been measured in blood, and indeed superior sensitivity and specificity have been found in several studies when compared to current surveillance methods. However, a variety of factors currently limit the immediate application of these exciting biomarkers. In this review, we provide a detailed rationalisation of the approach and basis for the use of methylation biomarkers for HCC detection and summarise recent studies on methylated DNA markers in HCC focusing on the importance of the aetiological cause of liver disease in the mechanisms leading to cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.